



ProSanos Releases SÆFETYWORKS™

New Software System Aims to Improve Drug Safety

"In a post-market environment, robust well-designed technologies like SÆfetyWorks™ can be an important part of the solution to the challenges of drug safety surveillance."

Jonathan Morris, MD, President and CEO of ProSanos Corporation

ProSanos Corporation announced in August the release of SÆfetyWorks™, a web-based software system that can help scientists more quickly spot and measure the strength of associations between a drug and a medical condition. Pioneered by GlaxoSmithKline plc (GSK) and ProSanos, and several years in development, SÆfetyWorks™ is now available to all drug safety professionals.

The new software system complements traditional epidemiologic studies and is an efficient way to monitor drugs once they've been introduced into the marketplace. Using SÆfetyWorks™, drug safety experts will have the unprecedented ability to ask the same questions of different electronic healthcare databases. Data from traditional sources, like adverse event reports and epidemiological studies, can quickly and reliably be compared with information from observational sources like insurance claims and electronic medical records.

Commenting on the co-development collaboration with ProSanos, Edward Pattishall, M.D., VP Safety

at GSK stated, "GSK is committed to enhancing patient safety and anticipates this tool will be extremely helpful in evaluating the benefit/risk profile of our medicines using multiple data sources that can't currently be easily and quickly compared. It is an improvement over other software solutions because it can rapidly and simultaneously interrogate multiple databases and contribute to the evidence of a potential safety issue..."

Jonathan Morris, M.D., President and CEO of ProSanos Corporation stated "In a post-market environment, robust well-designed technologies like SÆfetyWorks™ can be an important part of the solution to the challenges of drug safety surveillance. ProSanos looks forward to deploying the system with other participants in the process, so that even larger numbers of patients might benefit."


For more information visit www.prosanos.com.

ProSanos Corporation is an LSGPA portfolio company headquartered in Harrisburg, PA.


Also in this issue



PAGE 2



PAGE 3



PAGE 4

1 ProSanos Launches SÆfetyWorks **2** Grand Opening | College Venture Winner | New SBIR Opportunities **3** PA Ranks No. 1 | Bioscience Employment & Investment Data **4** Events Calendar

Harrisburg University's New Academic Center.



Innovative by Design.

Harrisburg University of Science and Technology will open its new \$73-million, 16-story Academic Center on the corner of Fourth and Market Streets in Harrisburg on December 10.

The 371,000 square foot structure features state-of-the-art classroom space, scientific teaching labs, meeting areas, seminar rooms, parking, and a 125-seat auditorium. It will promote modern

learning amenities like wireless Internet access and video-conferencing while giving students access to a new 20,000 volume library and an open courtyard designed for studying and mingling between classes.

The Academic Center also will house headquarters for the National Center for Science and Civic Engagement.

For more information email:
CONNECT@HarrisburgU.net

*College Venture Winner



Maricarmen Planas-Silva, PhD, an MBA student at Penn State Harrisburg, was the graduate-level winner of this year's College Venture Challenge, a business plan competition organized by The Harrisburg Regional Chamber & CREDC in cooperation with the Harrisburg Market Keystone Innovation Zone. Planas-Silva won for her concept for *BioCells2Cure*, which is aimed at ensuring that women diagnosed with advanced breast cancer receive the most effective drug treatment.

A new SBIR Opportunity from the National Cancer Institute: *The Bridge Award*

In an effort to accelerate the development and commercialization of novel therapies and imaging technologies that will help in the fight against cancer, the National Cancer Institute (NCI) has announced a pilot initiative to bridge the funding gap many early-stage biomedical companies face as they advance their technologies.

Known as the **Bridge Award**, the initiative is a targeted effort of the newly created NCI Small Business Innovation Research (SBIR) Development Center. It is designed to offer greater support for small business applicants, foster partnerships and collaborations between small businesses and third-party organizations, mentor SBIR-funded companies in commercialization and strategy, and ultimately accelerate the development of novel technologies and products to prevent, diagnose, and treat cancer. It more than triples the amount of funding available to small businesses through

the NCI SBIR Program, already one of the largest sources of early-stage technology financing in the United States.

Improving the translation of promising laboratory findings into the clinic is a top NCI priority. This new initiative will help more early-stage cancer treatments reach human clinical trials. In addition to being a top NCI priority, movement toward clinical trials is a key milestone in attracting corporate partners and institutional investors. By providing half of the resources needed to advance cancer therapies and cancer imaging technologies through some of the early, capital-intensive, pre-clinical stages, the NCI is helping reduce the risks to investors.

Small businesses that have previously received SBIR Phase II funding through the National Institutes of Health's SBIR Program are eligible to apply for up to \$3 million over three years through the Bridge Award.

*There are currently three receipt dates for Bridge Award applications — **September 19, 2008; November 3, 2008; and February 27, 2009.** To learn more about NCI's SBIR Program and the Bridge Award, go to <http://sbir.cancer.gov> or call the NCI Office of Media Relations to arrange an interview with NCI's SBIR Director, Michael Weingarten.*

Business Facilities Magazine Ranks PA No. 1 in Biotechnology

The July 2008 issue of *Business Facilities* magazine identified Pennsylvania as the leading state in biotechnology, as measured by a combination of more than 20 key criteria, including: the amount of state R&D funding and venture capital investments; the level of concentrated occupational employment in biotech; tax exemptions specifically targeted to biotech; the number of biotech facilities; biotech patents generated; university grant funding; and bioscience higher education degrees, among other factors.

Overall Biotechnology Strength, U.S., According to Business Facilities Magazine, July 2008.

PA

Ranked #1.

CALIFORNIA

Ranked #2.

ohio texas illinois

Ranked #3, #4 and #5, respectively.

NJ NY

Ranked #6. Ranked #7.

florida

Ranked #8.


KANSAS MINNESOTA

Ranked #9 and #10, respectively.

U.S. Employment by Bioscience Subsector

2001 EMPLOYMENT compared to 2006 EMPLOYMENT (In thousands).


Source: Battelle analysis of BLS, QCEW data from the Minnesota IMPLAN Group.



Adapted from *Technology, Talent and Capital: State Bioscience Initiatives 2008*. Prepared for BIO by Battelle Technology Partnership Practice, June 2008.

Bioscience Venture Capital Investments, 2002 – 2007

VENTURE CAPITAL INVESTMENTS (In millions)



Bioscience Venture Capital Investments, 2002-2007. Adapted from *Technology, Talent and Capital: State Bioscience Initiatives 2008*. Prepared for BIO by Battelle Technology Partnership Practice, June 2008.



**LIFE SCIENCES GREENHOUSE
of Central Pennsylvania**

www.lsgpa.com

225 Market Street | Suite 500
Harrisburg, PA 17101

PRSR STD
U.S. POSTAGE
PAID
HARRISBURG, PA
PERMIT NO. 533

If you are receiving this publication in error, or wish to be removed from our mailing list, please contact info@lsgpa.com. For information about funding opportunities and business support services provided by the Life Sciences Greenhouse of Central Pennsylvania, visit us online at www.lsgpa.com.

Events Calendar



SEPTEMBER 25
CEO Roundtable
Malvern, PA
www.pennsylvaniabio.org



OCTOBER 23
Building an Early-Stage
Life Sciences Business
Bethlehem, PA
www.lsgpa.com



OCTOBER 30
Building an Early-Stage
Life Sciences Business
Hershey, PA
www.lsgpa.com



NOVEMBER 10-11
Biotech 2008
Philadelphia, PA
www.biotech2008.org



NOVEMBER 12
Building an Early-Stage
Life Sciences Business
State College, PA
www.lsgpa.com

The Life Sciences Greenhouse is a public/private venture whose mission is to commercialize bioscience technologies. Clients include university-based researchers and technology development groups, emerging companies, and companies seeking to expand or relocate. LSGPA provides direct early-stage investment, targeted business development services, and connections to strategic partners.

